Ostarine (MK-2866) — effects, side effects and dosage
01 Mar
Ostarine, also known by the research designation MK-2866, is the most studied and widely used SARM on the market. Developed by the company GTx Inc. for the treatment of muscle atrophy and osteoporosis, the substance has undergone Phase II clinical trials in humans — something few other SARMs can claim. That makes Ostarine the SARM with the most human data to lean on, which doesn’t mean it’s risk-free but that the state of knowledge is better than most alternatives. We go through how MK-2866 works, what results you can expect, how it is dosed and what side effects research and user experiences have identified.
Mechanism of action — selective androgen receptor binding
Ostarine is a selective androgen receptor modulator in the strictest sense of the word. It binds to the androgen receptor in skeletal muscle and bone tissue and activates it — in the same way as testosterone — but with a significantly lower affinity for androgen receptors in the prostate, sebaceous glands, hair follicles and other androgen-sensitive tissues.
The selectivity is what separates SARMs from anabolic steroids. Testosterone and its derivatives activate the androgen receptor everywhere in the body without discrimination, producing the well-known side effects: acne, hair loss, prostate damage, liver stress and virilization in women. Ostarine provides a milder, more targeted anabolic signal that in theory builds muscle tissue without affecting other organs to the same extent.
The word “in theory” is deliberately chosen. The selectivity is not absolute — it is relative. At higher doses and longer periods, selectivity decreases, and the risk of systemic androgenic effects increases. It is a dose-response relationship that is important to understand: Ostarine at 3 mg per day behaves differently in the body than Ostarine at 25 mg per day, and the difference is not only about the strength of the effect but about which tissues are affected.
Effects — what research and experience show
Ostarine’s effects have been documented in three contexts: clinical studies, preclinical models, and anecdotal user experience. All point in the same direction, albeit with different degrees of precision.
In a phase II study in elderly men and women with muscle wasting, Ostarine doses of 1 mg and 3 mg per day showed a significant increase in total lean body mass by 1.3-1.4 kg after 12 weeks, compared to placebo. The improvement occurred without structured exercise — participants were simply asked to maintain their usual activity levels. It suggests that Ostarine has a direct anabolic effect on the muscles independent of physical load.
Users who combine MK-2866 with strength training report effects that exceed what studies show at low doses. The most common observations include a gradual increase in strength over the first 3-4 weeks, improved muscle tone and definition, faster recovery between workouts, better joint feeling — especially in the knees and shoulders — and a modest but noticeable reduction in body fat. The effects are consistently described as mild to moderate compared to stronger SARMs such as RAD-140 or LGD-4033, but with a more favorable side effect profile.
Ostarine has also shown promising results for bone health. Preclinical studies demonstrate increased bone density and improved bone mineralization, which was one of the primary research indications. For active individuals with joint problems or previous stress fractures, this feature can be just as valuable as the muscle-building effect.
A realistic expectation for a typical Ostarine period (25 mg per day for 8 weeks) with regular strength training and adequate diet: 2-3 kg of increased muscle mass, 1-2 kg of reduced body fat and a noticeable increase in exercise strength. These are not dramatic numbers compared to anabolic steroids, but they are measurable results with a side effect profile that is significantly milder.
Ostarine dosage — protocol and time frames
Ostarine does not have an approved medical dosage, which means that all dosage information is based on clinical studies (where doses were 1–3 mg) and the extensive experience of the research and training community (where doses are typically higher).
Nybörjardosen som de flesta rekommenderar är 10–15 mg per dag. It provides a noticeable effect with minimal hormonal influence and is a conservative starting position for those who want to evaluate their individual response. Experienced users often apply 20–25 mg per day, which is considered the standard dose in most protocols. Doses above 30 mg per day are not considered to give proportionally better results but significantly increase the risk of hormonal suppression.
Period length varies between 6 and 12 weeks, with 8 weeks being the most common choice. Shorter periods of 6 weeks may suffice at lower doses, while 12 weeks are applied by experienced users at higher doses who want to maximize the period. Longer periods than 12 weeks are not recommended — the risk of cumulative hormonal influence increases and the effect tends to plateau.
Ostarine’s half-life is estimated to be 24 hours, which means that a single daily dose is sufficient. Most people take it in the morning, but the time has no significant effect on the effect. Consistency is more important than timing — pick a time that fits your routine and stick to it. Ostarine can be taken with or without food; absorption is not significantly affected by the contents of the gastrointestinal tract.
Ostarine side effects — what you need to know
Ostarine’s side effect profile is milder than most other SARMs, but not non-existent. The most important side effect to understand and manage is hormonal suppression — the temporary downregulation of the body’s own testosterone production.
Testosterone suppression occurs in most users at doses above 10 mg per day for 8 weeks or longer. The degree varies individually, but blood tests typically show a 20-50% drop in total testosterone over the period. It sounds dramatic but is qualitatively different from the heavy suppression that anabolic steroids cause. Most people recover within 4-6 weeks of finishing the period without specific PCT (post cycle therapy), but blood tests are strongly recommended to confirm.
SHBG (sex hormone binding globulin) lowering is observed in clinical studies with Ostarine. Lower SHBG means more testosterone is freely available — paradoxically, this can initially mask the underlying suppression and give a false sense of well-being during the period.
HDL cholesterol tends to drop during a period of Ostarine, often by 15-30%. The effect is reversible but should be monitored, especially in individuals with existing lipid disorders. LDL cholesterol is affected to a lesser extent.
Other reported side effects include mild headache during the first few days, slight dryness of the mouth, and temporarily altered sleep. Liver enzymes (ALT and AST) may rise marginally but usually remain within the normal range at recommended doses. Serious hepatotoxicity has not been reported in clinical studies with Ostarine, which distinguishes it from oral anabolic steroids that are 17-alpha-alkylated.
Ostarine and PCT — is it necessary?
The question of PCT (post cycle therapy) after Ostarine is re-debated. Conservative users always advocate a mild PCT with, for example, Nolvadex (tamoxifen) 20 mg per day for 4 weeks. Others argue that Ostarine’s mild suppression does not justify PCT at doses below 25 mg and periods below 8 weeks.
Our recommendation: take a blood test. A simple hormone panel (testosterone, LH, FSH, SHBG) 2–3 weeks after the end of your period gives you concrete data to base the decision on. If the testosterone has fallen sharply (below 8–10 nmol/L), a short PCT is justified. If it is within the normal range but in the lower part, you can wait and take a follow-up test after another 3-4 weeks.
Blood test-based decision-making replaces guesswork with facts — and that’s always preferable when it comes to hormones. Ostarine finns i vårt sortiment som forskningskemikalie för den som vill utforska substansen vidare, och en översikt av SARMs för gymmet kan ge ytterligare perspektiv om du överväger vilken substans som passar dina mål.
.entry-content